Your Monthly Medicines Roundup for January 2026
Your Monthly Medicines Roundup for January 2026
Similar to December 2025, January 2026 was a quiet month in terms of medicines for inherited metabolic disorders being appraised. Only an update for a potential new treatment option for familial chylomicronemia syndrome was issued. We also look at what other updates we expect to see in 2026.
Osteogenesis Imperfecta
Setrusumab for treating osteogenesis imperfecta has been identified for assessment by NICE in England as a potential new treatment to be assessed. We currently do not have any information on timelines and will update the community as soon as more information is available.
Further details can be found on the NICE website:
Primary hypercholesterolaemia or mixed dyslipidaemia
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia has been identified by NICE in England. Patient organisations, companies and other organisations with an interest in this condition have been invited to participate. The timelines for the appraisal have also been published, with the first committee meeting scheduled for the 4th of August, followed by an expected decision on the 14th of October 2026.
Further details can be found on the NICE website:
